Lasofoxifene tartrate

Basic Information

View in Editor

CAS Number

190791-29-8

Molecular Formula

C32H37NO8

Molecular Weight

563.65 g/mol

Chemical Classification

Basic Chemical Raw Materials Organic Chemicals Carboxylic Acids

Basic Chemical Raw Materials Organic Chemicals Ethers

Basic Chemical Raw Materials Organic Chemicals Heterocyclic Compounds

Pharmaceutical Chemicals Pharmaceutical Intermediates Heterocyclic Intermediates

Fine Chemicals Dyes and Pigments Organic Dyes

Fine Chemicals Surfactants Anionic Surfactants

Laboratory Chemicals Research Chemicals Biochemical Reagents

Basic Physical Properties

Physical State

No data available

Melting Point

No data available

Boiling Point

No data available

Flash Point

No data available

Solubility

DMSO: soluble10mg/mL, clear

Vapor Pressure

No data available

SMILES

View in Editor

C1CCN(C1)CCOC2=CC=C(C=C2)C3C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5.C(C(C(=O)O)O)(C(=O)O)O

InChI

InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

InChIKey

INEHJXCWEVNEDZ-LUDNRVPPSA-N

LogP

3.606100000000003

Topological Polar Surface Area

147.76 Å²

Hydrogen Bond Donor/Acceptor

5 / 9

Complexity

667

Safety Information

View Safety Information

Hazard Statement

H302 Harmful if swallowed
Acute toxicity, oral

H315 Causes skin irritation
Skin corrosion/irritation

H319 Causes serious eye irritation
Serious eye damage/eye irritation

H335 May cause respiratory irritation
Specific target organ toxicity, single exposure; Respiratory tract irritation

Synonyms & References

English

UNII-85X09V2GSO
(5R,6S)-6-phenyl-5-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,6,7,8-tetrahydronaphthalen-2-ol (2S,3S)-2,3-dihydroxysuccinate
L0336
AS-75192
(2S,3S)-2,3-dihydroxybutanedioic acid; (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, cis-(-)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt)
(2S,3S)-2,3-dihydroxybutanedioic acid;(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
Lasofoxifene tartrate
Z2787995378
LASOFOXIFENE TARTRATE [JAN]
HY-A0038
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)
AKOS030230851
Lasofoxifene tartrate [USAN]
LASOFOXIFENE TARTRATE [MI]
CS-5274
DTXSID60940655
LASOFOXIFENE TARTRATE [MART.]
Lasofoxifene tartrate, >=98% (HPLC)
CP-336156
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, (5R-cis)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (salt)
MFCD30207839
LASOFOXIFENE TARTRATE [WHO-DD]
Q27269679
CP-336156-CB
SCHEMBL1649247
190791-29-8
2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1)
AM84656
Lasofoxifene (Tartrate)
Fablyn

MDL Number

MFCD13185249

FAQ

What regulatory guidelines apply to lasofoxifene tartrate (CAS: 190791-29-8)?

Lasofoxifene tartrate (CAS: 190791-29-8) is subject to regulatory guidelines under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for hazardous substances. Additionally, it falls under the scope of the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations in the European Union. In the United States, it may be regulated by the Food and Drug Administration (FDA) for pharmaceuticals and the Environmental Protection Agency (EPA) for environmental safety.

Are there alternatives to lasofoxifene tartrate (CAS: 190791-29-8) in synthesis?

In the synthesis of lasofoxifene tartrate (CAS: 190791-29-8), alternative reagents and methods may include the use of similar estrogen agonists such as raloxifene or bazedoxifene. Isomers or analogs of lasofoxifene may also be considered, but thorough structural and functional analysis is required to ensure the desired pharmacological properties are maintained.

What is the market or research trend for lasofoxifene tartrate (CAS: 190791-29-8)?

The market for lasofoxifene tartrate (CAS: 190791-29-8) is primarily driven by its use as a selective estrogen receptor modulator (SERM) in the treatment of osteoporosis and menopausal symptoms. Research trends are focused on understanding its pharmacokinetics, therapeutic efficacy, and potential side effects. Recent studies are also exploring its role in preventing bone loss and its safety profile in different patient populations.

How should waste containing lasofoxifene tartrate (CAS: 190791-29-8) be handled?

Waste containing lasofoxifene tartrate (CAS: 190791-29-8) should be collected in appropriate containers and stored separately to prevent contamination. Disposal should follow environmental protection guidelines, typically involving incineration at a licensed waste treatment facility or professional waste disposal. All handling and disposal procedures must comply with local and international regulations, including GHS and REACH guidelines, to ensure safety and environmental protection.